Investigational Drug Information for Aclarubicin
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Aclarubicin?
Aclarubicin is an investigational drug.
There have been 12 clinical trials for Aclarubicin.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2021.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Huihan Wang, Sun Yat-sen University, and The Second People's Hospital of Huai'an.
There are seven hundred and forty-three US patents protecting this investigational drug and eleven international patents.
Summary for Aclarubicin
| US Patents | 743 |
| International Patents | 11,296 |
| US Patent Applications | 2,120 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 4,533 |
| Clinical Trial Progress | Phase 1 (2021-03-01) |
| Vendors | 26 |
Recent Clinical Trials for Aclarubicin
| Title | Sponsor | Phase |
|---|---|---|
| A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients | Hematology department of the 920th hospital | Phase 1/Phase 2 |
| Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study | Huihan Wang | N/A |
| Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial | Huihan Wang | Phase 3 |
Clinical Trial Summary for Aclarubicin
Top disease conditions for Aclarubicin
Top clinical trial sponsors for Aclarubicin
US Patents for Aclarubicin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Aclarubicin | See Plans and Pricing | Heterocyclic compounds useful in the treatment of disease | Epigen Biosciences, Inc. (San Diego, CA) | See Plans and Pricing |
| Aclarubicin | See Plans and Pricing | Heat shock protein 70 (hsp-70) receptor ligands | Duke University (Durham, NC) | See Plans and Pricing |
| Aclarubicin | See Plans and Pricing | Compounds and their methods of use | Agios Pharmaceuticals, Inc. (Cambridge, MA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Aclarubicin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Aclarubicin | Australia | AU2014232383 | 2033-03-15 | See Plans and Pricing |
| Aclarubicin | Australia | AU2019202731 | 2033-03-15 | See Plans and Pricing |
| Aclarubicin | Australia | AU2019288275 | 2033-03-15 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
